(Q33409392)

English

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase I clinical trial

0 references

3-[2-butyl-1-[2-(diethylamino)ethyl]-5-benzimidazolyl]-N-hydroxy-2-propenamide

1 reference

ChEBI release 2020-05-28

author name string

Alexandra P Zorzi

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mark Bernstein

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yvan Samson

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Donna A Wall

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sunil Desai

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Darcy Nicksy

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nancy Wainman

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Elizabeth Eisenhauer

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sylvain Baruchel

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

25 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pediatric Blood & Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1868-1874

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Epigenetic modifiers: basic understanding and clinical development.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Functions of site-specific histone acetylation and deacetylation

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Histone deacetylase inhibitors: molecular mechanisms of action

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Targeting histone deacetylase in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24694

21 January 2018

Identifiers

10.1002/PBC.24694

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33409392&oldid=1749478393"